The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

As the insulin pumps market evolves, advancements in technology and rising patient preference for these devices are set to ...

“Glucose-responsive – so-called smart – insulins are regarded as the holy grail of insulin as they would come as close to a ...

CHICAGO -- Hormone therapy for menopause symptoms reduced insulin resistance in healthy postmenopausal women, a systematic ...

Diabetes affects over 37 million people in the U.S., with many of them living with type 2 diabetes. This form of diabetes ...

Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

In the trial, efsitora met the primary endpoint of non-inferior A1C reduction. For the efficacy estimand, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec resulting in an A1C of ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Key drivers include technological advancements and evolving healthcare policies. The global market for short-acting insulin ...

Diabetes affects millions of Americans, with 1.4 million new cases diagnosed each year. This chronic condition is one of the ...